References
- Mountifield R, Bampton P, Prosser R, Muller K, Andrews JM. Fear and fertility in inflammatory bowel disease: a mismatch of perception and reality affects family planning decisions. Inflamm Bowel Dis 2009;15:720–5.
- Zelinkova Z, Baars J, Marcus T, Kuipers EJ, van der Woude CJ. Female perception of the quality of life differs from male inflammatory bowel disease patients. Gut 2007;39(Suppl I):A145.
- Baird DD, Narendranathan M, Sandler RS. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology 1990;99:987–94.
- Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:591–9.
- Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 2007;26:513–33.
- Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23–8.
- Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55(Suppl 1):i36–58.
- Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology 1994;49:79–81.
- Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004;99:656–61.
- Marteau P, Tennenbaum R, Elefant E, Lémann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther 1998;12:1101–8.
- O'Donnell S, O'Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther 2008;27:885–94.
- Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4:1255–8.
- Mahadevan U, Terdiman JP, Church J, Vasiliauskas E, Gitis A, Dubinsky MC. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007;132(Suppl 2):A144.
- Oussalah A, Roblin X, Laharie D, Filippi J, Flamant M, Faure P, Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey. Aliment Pharmacol Ther 2009 Jul 14; Epub ahead of print.
- Zankel E, Rogler G, Andus T, Reng CM, Schölmerich J, Timmer A, Crohn's disease patient characteristics in a tertiary referral center: comparison with patients from a population-based cohort. Eur J Gastroenterol Hepatol 2005;17:395–401.